Biodesix, Inc. (NASDAQ:BDSX) Director Purchases $234,000.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack W. Schuler purchased 200,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $234,000.00. Following the completion of the purchase, the director now owns 31,094,935 shares in the company, valued at approximately $36,381,073.95. The trade was a 0.65 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Biodesix Trading Up 6.7 %

Shares of Biodesix stock opened at $1.28 on Friday. Biodesix, Inc. has a 1-year low of $1.11 and a 1-year high of $2.21. The company’s fifty day simple moving average is $1.57 and its 200-day simple moving average is $1.61. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The stock has a market capitalization of $186.20 million, a PE ratio of -3.28 and a beta of 1.22.

Biodesix (NASDAQ:BDSX) last released its earnings results on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. During the same period in the previous year, the business earned ($0.12) earnings per share. As a group, equities analysts anticipate that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Analyst Ratings Changes

Separately, Scotiabank began coverage on Biodesix in a research report on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $3.06.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its holdings in Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares in the last quarter. Opaleye Management Inc. increased its stake in shares of Biodesix by 7.7% in the first quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after purchasing an additional 38,157 shares in the last quarter. CVI Holdings LLC bought a new stake in shares of Biodesix during the 2nd quarter valued at $59,000. Landscape Capital Management L.L.C. purchased a new position in shares of Biodesix during the 3rd quarter valued at $262,000. Finally, Geode Capital Management LLC boosted its holdings in Biodesix by 50.7% in the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after buying an additional 270,724 shares during the period. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.